OUTCOMES AND PREDICTORS OF CHRONIC IMMUNE CHECKPOINT INHIBITOR INDUCED INFLAMMATORY ARTHRITIS: DATA FROM THE CANADIAN RESEARCH GROUP OF RHEUMATOLOGY IN IMMUNO-ONCOLOGY (CANRIO) RETROSPECTIVE COHORT

被引:0
|
作者
Ladouceur, A. [1 ]
Arreola, L. Gonzalez [2 ]
Jamal, S. [2 ]
Hudson, M. [1 ]
Pope, J. [3 ]
Hoa, S. [4 ]
Roberts, J. [5 ]
Moon, D. [6 ]
Karmali, A. [2 ]
Nevskaya, T. [3 ]
Schmidt, E. [1 ]
Toban, N. [4 ]
Cho, L. [5 ]
Barnetche, T. [7 ]
Ye, C. [6 ]
机构
[1] McGill Univ Med, Montreal, PQ, Canada
[2] Univ British Columbia, Med, Vancouver, BC, Canada
[3] Univ Western Ontario, Med, London, ON, Canada
[4] Univ Montreal, Med, Montreal, PQ, Canada
[5] Dalhousie Univ, Med, Halifax, NS, Canada
[6] Univ Alberta, Edmonton, AB, Canada
[7] CHU Bordeaux, Med, Bordeaux, France
关键词
Inflammatory arthritides; Malignancy; Prognostic factors;
D O I
10.1136/annrheumdis-2023-eular.1018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
POS1567
引用
收藏
页码:1158 / 1159
页数:2
相关论文
共 22 条
  • [21] Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology
    Sabrina Hoa
    Linda Laaouad
    Janet Roberts
    Daniel Ennis
    Carrie Ye
    Karam Al Jumaily
    Janet Pope
    Tatiana Nevskaya
    Alexandra Saltman
    Megan Himmel
    Robert Rottapel
    Christina Ly
    Ines Colmegna
    Aurore Fifi-Mah
    Nancy Maltez
    Annaliese Tisseverasinghe
    Marie Hudson
    Shahin Jamal
    Cancer Immunology, Immunotherapy, 2021, 70 : 2197 - 2207
  • [22] USE OF A 27-GENE IMMUNO-ONCOLOGY (IO) ASSAY TO ASSOCIATE RESPONSE TO SINGLE-AGENT IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY IN ADVANCED-STAGE NSCLC PATIENTS FROM A LARGE CANADIAN COHORT
    Saltman, David
    Croteau, Nicole
    Lockyer, Heather
    Seitz, Rob
    McMahon, Frank
    Spille, Jeremy
    Dickey, Andrea
    Varga, Matthew
    McGregor, Kim
    Nielsen, Tyler
    Hout, David
    Schweitzer, Brock
    Ross, Douglas
    Gandara, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A495 - A495